# US 2004/0082503 A1 · Methods for treatment of diabetes using peptide analogues of insulin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082503 A1
- Document ID: US20040082503A1
- Status: Published application
- Kind: A1
- Application number: 10/339,160
- Filed: 2003-01-08
- Published: 2004-04-29
- Earliest claimed: 1998-02-23
- Assignees: Neurocrine Biosciences, Inc.
- Inventors: Amitabh Gaur; Nicholas Ling; Paul J. Conlon
- Web page: https://patentgrep.com/patent/US20040082503A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/62: Insulins
- C07K 14/622: {at least 1 amino acid in D-form}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.

## Claims

### Claim 1

A peptide analogue comprising residues 9 to 23 of human insulin B chain, wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at between 1 and 4 amino acid positions, and wherein at least one substitution occurs at a residue selected from the group consisting of residues 12, 13, 15 and 16.

### Claim 2 (depends on 1)

The peptide analogue of claim 1, wherein the peptide analogue has a sequence that differs from native human insulin B chain at two amino acid residues.

### Claim 3 (depends on 1)

The peptide analogue of claim 1, wherein the peptide analogue has a sequence that differs from native human insulin B chain at three amino acid residues.

### Claim 4 (depends on 1)

The peptide analogue of claim 1, wherein an amino acid substitution occurs at residue 19.

### Claim 5 (depends on 1)

The peptide analogue of claim 1, wherein at least one amino acid substitution is non-conservative.

### Claim 6 (depends on 1)

The peptide analogue of claim 1, wherein residue 12 is substituted.

### Claim 7 (depends on 6)

The peptide analogue of claim 6, wherein residue 12 is an alanine residue.

### Claim 8 (depends on 1)

The peptide analogue of claim 1, wherein residue 13 is substituted.

### Claim 9 (depends on 8)

The peptide analogue of claim 8, wherein residue 13 is an alanine residue.

### Claim 10 (depends on 1)

The peptide analogue of claim 1 wherein residue 15 is substituted.

### Claim 11 (depends on 10)

The peptide analogue of claim 10, wherein residue 15 is an alanine residue.

### Claim 12 (depends on 1)

The peptide analogue of claim 1, wherein residue 16 is substituted.

### Claim 13 (depends on 12)

The peptide analogue of claim 12, wherein residue 16 is an alanine residue.

### Claim 14 (depends on 6, 7, 8, 9, 10, 11, 12, 13)

The peptide analogue of any one of claims 6-13, wherein residue 19 is substituted.

### Claim 15 (depends on 14)

The peptide analogue of claim 14, wherein residue 19 is an alanine residue.

### Claim 16 (depends on 1)

The peptide analogue of claim 1, further comprising residue 24 of human insulin B chain.

### Claim 17 (depends on 1)

The peptide analogue of claim 1, wherein the peptide analogue comprises no more than 18 residues of human insulin B chain.

### Claim 18 (depends on 1)

The peptide analogue of claim 1, wherein the peptide analogue comprises no more than 16 residues of human insulin B chain.

### Claim 19 (depends on 1)

The peptide analogue of claim 1, wherein the peptide analogue comprises no more than 15 residues of human insulin B chain.

### Claim 20

A peptide analogue consisting essentially of residues 9 to 23 of human insulin B chain, wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at between 1 and 4 amino acid positions, and wherein at least one substitution occurs at a residue selected from the group consisting of residues 12, 13, 15 and 16.

### Claim 21

A peptide analogue consisting essentially of residues 9 to 24 of human insulin B chain, wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at between 1 and 4 amino acid positions, and wherein at least one substitution occurs at a residue selected from the group consisting of residues 12, 13, 15 and 16.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition comprising a peptide analogue according to any one of claims 1-19 in combination with a physiologically acceptable carrier or diluent.

### Claim 23 (depends on 22)

A method for inhibiting the development of diabetes, comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition according to claim 22.

### Claim 24 (depends on 22)

A method for treating diabetes, comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition according to claim 22.

### Claim 25

A peptide analogue comprising residues 9 to 23 of human insulin B chain, wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at residues 16 and 19.

### Claim 26 (depends on 25)

A pharmaceutical composition comprising a peptide analogue according to claim 25 in combination with a physiologically acceptable carrier or diluent.

### Claim 27 (depends on 26)

A method for inhibiting the development of diabetes, comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition according to claim 26.
